We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


Tests under development

(will be referred on by us until in-house testing is validated)

  • JAK2 exon 12
  • BCR-ABL mutation screen for the ABL kinase domain to provide information on drug resistance and to indicate changes that may be required in therapy based upon the mutation indicated
  • Other new and established target genes as required for the molecular work up indicated by standard and best practice relating to leukaemia and lymphoma
  • Next generation sequencing to assess increased panels of genes for diagnostic profiling to risk stratify patients for specific treatment options
  • The above gene panel tests will be influenced by NHS E Test Directory requirements


(Last reviewed 12th February 2018)